Replies to post #192 on Equity Field Notes from temporal sources

[DanWebzster]

ONVO is one of those shit-cap companies that is easy to lose track of due to a perception of futility.

Its treatment for alpha-1-antitrypsin deficiency was granted FDA orphan status. ONVO targets fiscal 2020 for filing an NDA for this treatment

Success with this program would legitimize its focus on the $4B market for therapeutic alternative to organ transplants.

ONVO is seeking a 2nd IND-track program in orphan liver disease.

Cash = $44mn while burning ~$6mn / Q, giving them a runway deep into fiscal 2020